We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
10 own
8 watching
Current Price
$1.02
$-0.03
(-2.86%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
64.81M
52-Week High
6.12
52-Week Low
0.87
Average Volume
0.08M
Dividend Yield
--
P/E Ratio
--
Market Capitalization64.81M
52-Week High6.12
52-Week Low0.87
Average Volume0.08M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain s energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
19days ago
Secondary survival endpoint for the CNM-Au8 30 mg dose investigated in the Healey ALS Platform Trial demonstrated a >90% reduction in the risk of death or death equivalent (permanently assisted ventilation) and risk of death alone at 24 weeks. This survival benefit was consistent with prior results ...
Zolmax
20days ago
Clene Inc. (NASDAQ:CLNN Get Rating) Director David J. Matlin purchased 2,871,287 shares of the stock in a transaction dated Wednesday, November 2nd. The shares were purchased at an average price of $1.01 per share, with a total value of $2,899,999.87. Following the transaction, the director now ...
Globe Newswire
26days ago
SALT LAKE CITY, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries Clene) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative disease, today announced ...
Ticker Report
1month ago
Clene Inc. (NASDAQ:CLNN Get Rating) was the target of some unusual options trading on Thursday. Investors bought 9,009 put options on the stock. This represents an increase of 122% compared to the average volume of 4,065 put options. Analyst Ratings Changes CLNN has been the topic of a ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$1.02
$-0.03
(-2.86%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00